» Articles » PMID: 36839573

Employing T-Cell Memory to Effectively Target SARS-CoV-2

Overview
Journal Pathogens
Date 2023 Feb 25
PMID 36839573
Authors
Affiliations
Soon will be listed here.
Abstract

Well-trained T-cell immunity is needed for early viral containment, especially with the help of an ideal vaccine. Although most severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected convalescent cases have recovered with the generation of virus-specific memory T cells, some cases have encountered T-cell abnormalities. The emergence of several mutant strains has even threatened the effectiveness of the T-cell immunity that was established with the first-generation vaccines. Currently, the development of next-generation vaccines involves trying several approaches to educate T-cell memory to trigger a broad and fast response that targets several viral proteins. As the shaping of T-cell immunity in its fast and efficient form becomes important, this review discusses several interesting vaccine approaches to effectively employ T-cell memory for efficient viral containment. In addition, some essential facts and future possible consequences of using current vaccines are also highlighted.

References
1.
Mikacenic C, Hansen E, Radella F, Gharib S, Stapleton R, Wurfel M . Interleukin-17A Is Associated With Alveolar Inflammation and Poor Outcomes in Acute Respiratory Distress Syndrome. Crit Care Med. 2015; 44(3):496-502. PMC: 4764422. DOI: 10.1097/CCM.0000000000001409. View

2.
Attanasio J, Wherry E . Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease. Immunity. 2016; 44(5):1052-68. PMC: 4873956. DOI: 10.1016/j.immuni.2016.04.022. View

3.
Loretelli C, Abdelsalam A, DAddio F, Ben Nasr M, Assi E, Usuelli V . PD-1 blockade counteracts post-COVID-19 immune abnormalities and stimulates the anti-SARS-CoV-2 immune response. JCI Insight. 2021; 6(24). PMC: 8783674. DOI: 10.1172/jci.insight.146701. View

4.
Han S, Asoyan A, Rabenstein H, Nakano N, Obst R . Role of antigen persistence and dose for CD4+ T-cell exhaustion and recovery. Proc Natl Acad Sci U S A. 2010; 107(47):20453-8. PMC: 2996637. DOI: 10.1073/pnas.1008437107. View

5.
Dutta N, Mazumdar K, Gordy J . The Nucleocapsid Protein of SARS-CoV-2: a Target for Vaccine Development. J Virol. 2020; 94(13). PMC: 7307180. DOI: 10.1128/JVI.00647-20. View